Nestec SA, a subsidiary of Nestlé SA, is a Swiss company located in Vevey. The firm manufactures nutrition food products.

Breath Therapeutics – a Zambon Group Company is pursuing groundbreaking therapies by unleashing the true potential of inhaled drug delivery. Their approach combines novel formulations of existing drugs with cutting-edge inhalation technology for the treatment of rare respiratory diseases with high unmet medical need. They are developing drug-device combinations designed to rapidly deliver high concentrations of drugs to the site of action in the lung. Their approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety.

Part of Mereo BioPharma Group Plc, Mereo BioPharma 4 Ltd. is a British company located in London that provides biotechnological research and development services. The firm was founded in 2017.

Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections. The company also focused on the development and commercialization of nitric oxide (NO) formulations for the treatment of lung infections. The revolutionary respiratory-targeted generator and delivery system, LungFit is designed to generate and effectively deliver nitric oxide to intubated and non-intubated patients in both the hospital and the home setting. The LungFit system uses proprietary technology to generate nitric oxide from ambient air and transform the lives of patients with respiratory conditions and severe lung infections. It can deliver nitric oxide either continuously or intermittently with the ability to titrate on demand. The system also satisfies a strong desire to eliminate cylinders from the hospital, providing significant benefits as a result. Beyond was founded in 2011 and is headquartered in Garden City, NY, USA.

Société des Produits Nestlé SA engages in the manufacture and distribution of food, pharmaceutical, medical, and cosmetic products. The company was founded on December 15, 1936 and is headquartered in Vevey, France.

Inspire Pharmaceuticals, Inc. is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The advanced compounds in the clinical pipeline are denufosol tetrasodium for cystic fibrosis and Prolacria for dry eye, both of which are in Phase III development, and AzaSite for blepharitis, which is in Phase II development.

Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Drugrecure ApS, a subsidiary of Savara, Inc., is a Danish company that provides health care services.

Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline includes several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration is the first such trial for an siRNA drug.

Founded in 1994, Quark devoted its early years to developing its innovative technology platform for identification of novel functional target genes and proteins, the “BiFAR” technology. The basic concept, patented by Quark, of high throughput gene inactivation combined with microarray detection of the functional genes responsible for the occurrence of phenotypes of interest, was at that time revolutionary. With the advent of siRNA technology, Quark's approach is rapidly becoming the technology of choice for functional studies industry-wide. We have applied our BiFAR platform in gene discovery programs in serious diseases with significant unmet medical needs, often in collaboration with large pharmaceutical partners. Today we are harvesting the fruits of the innovative targets and concepts we identified.

WHANIN Pharmaceutical is a pharmaceutical company that develops, manufactures, markets, and sells the therapeutic products. WHANIN originally focused on the psychiatric and neurological diseases. Recognizing new opportunities in CNS disorders, WHANIN is concentrating on bringing the new products and technologies for the patients suffering from such CNS disorders. During the past quarter of the century in the healthcare professionals and Korean community, WHANIN is engraved as one of the best local pharmaceutical companies which dedicates to supplying the social and medical communities with the quality products.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Onspira Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of medicines for patients suffering from rare pulmonary diseases. Its model leverages internal, external and shared expertise to efficiently advance promising medicines against clear and validated targets where there are unmet medical needs. Patients are at the very center of what they do and their urgency is driven by our passion to make a real difference. The company's team is united in the belief that they can do more for patients with rare and serious pulmonary disorders, and that these patients deserve to have active, rich and fulfilling lives.

University Hospital Freiburg is a healthcare organization that offers research, education, clinical practice, and treatment programs. Freiburg University Medical Center ensures the possible care for their patients by bundling their knowledge from clinical practice, research, and teaching. Their scientific work aims at the responsible and at the same time rapid introduction of new therapies that save lives and maintain quality of life. Their university clinic offers the medical offspring limitless opportunities to expand their knowledge. It is founded in 1457 in Freiburg, Germany.

Part of Danone SA, Nutricia NV is a Dutch company located in Zoetermeer that manufactures dry, condensed and evaporated dairy products.

Research International is a market research company that enables client companies to identify new growth opportunities. The company is focused on sectors that include automotive, beverage, consumer packaged goods, energy and utilities, financial services, healthcare, new media, retail, and technology. Research International had offices in 50 countries and employs approximately 2,500 people across the world. Research International's genesis was the market research division of Unilever. Research International was founded in 1962 by Eileen Cole. The company was later merged with TNS, which has been acquired by WPP.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Trimunocor is a dynamic spin-out formed to leverage innovations from the Medical Research Council and the University of Southampton focused on finding solutions to combat neonatal chronic lung disease. Our primary innovation centres around the development of natural anti-inflammatory and anti-microbial protein surfactant, protein D for a broad range of anti-inflammatory lung diseases. To deliver this innovation our team brings together world leading scientific talent, expansive clinical networks and renowned commercial experience together into a team that is poised to deliver exceptional results.

Bio Response, Inc. is a private company headquartered in Brooklyn, NY, with domestic subsidiaries. The firm provides marketing and distribution services.